We offer real medicine, real results, and real support every step of the way.
But, Yanovski cautions, its still early days. Amid the hubbub, a fresh influx of clinical trial data has opened a Pandoras box of questions
Any concerning symptomssuch as severe persistent nausea, inability to tolerate oral intake, signs of dehydration, severe abdominal pain, or right upper quadrant pain (which could indicate gallbladder disease)warrant prompt communication with the prescribing healthcare provider
Retatrutide is an unlicensed investigational tri-agonist (GLP-1, GIP, glucagon) with no MHRA or EMA marketing authorisation as of 2024
Last week, Kenlys compounding pharmacists informed her that, because tirzepatide was no longer on the shortage list, they would need to stop making the compounded versions or seek out a different supplier
The FDA receives data from drugmakers about their ability to supply the market with commercial medications